Upload
institute-for-health-metrics-and-evaluation-university-of-washington
View
102
Download
0
Embed Size (px)
DESCRIPTION
GHME 2013 Conference Session: New directions in cost-effectiveness analysis Date: June 16 2013 Presenter: Dean Jamison Institute: Center for Disease Dynamics, Economics & Policy University of Washington Department of Global Health
Citation preview
Including Financial Protection and Equity in Health CEAs
Dean T. JamisonUniversity of Washington, Department of Global Health
Global Health Metrics and Evaluation ConferenceJune 16, 2013
104/10/2023
04/10/2023
Plan for this Talk
• Conceptual background
• Public finance of TB treatment of India
2
04/10/2023
Outcomes of a Policy
3
• Health gains (burden of disease averted)
• Financial protection benefits (“insurance” to households from medical impoverishment)
• Income consequences for households
• Distributional consequences (across income groups, ethnic subgroups or between males and female)
04/10/2023
Evaluation of Policy:Extended Cost-Effectiveness
Analysis (ECEA)
4
• Evaluation of interventions and platforms (CEA)(e.g. DOTS as an intervention surgical capacity at a district hospital as a
platform)
• Evaluation of Policies
04/10/2023 5
Policies
• Taxes and subsidies(e.g. universal public finance; tobacco taxes)
• Laws and regulation• Investment in capacity• Information and education
04/10/2023 6
Financial Risk Protection 1
• Enthoven (1987) stressed importance of FRP as a health system objective.
• Metrics include:• Incidence of impoverishment, excessive spending,
forced borrowing and forced asset sales (Wagstaff reviews results)
• Money-metric value of insurance
04/10/2023
Financial Risk Protection (2) Insurance
7
• Risk aversionIndividuals value protection from the risk of uncertain adverse events
y = individual incomer = coefficient of relative risk aversion
• Approach consistent with recent workMcClellan & Skinner. The incidence of Medicare.
Journal of Public Economics 2006 Smith. Incorporating financial protection into the economic evaluation of health technologies. Health Economics 2012
04/10/2023 8
Financial Risk Protection (3)
• Money-metric value of insurance providedGamble with:- disease occurs at incidence p (depending on income)
- has treatment cost c
• For 1 individual, money-metric value of insurance = expected value - certainty equivalent of gamble
04/10/2023
ECEA Structure
9
Policy Instrument
Health gains
(e.g. TB deaths averted)
Household expenditures
(e.g. TB-related costs
averted)
“Insurance” benefits(e.g. financial
protection from TB-related costs)
Poorest 2nd Poorest Middle 2nd Richest Richest
04/10/2023
Universal public finance of TB treatment in India
Work undertaken with Stéphane Verguet and Ramanan Laxminarayan
10
04/10/2023
Tuberculosis in India
11
• TB epidemiologyAnnual incidence of 100 per 100,000 (sputum smear-positives) (WHO
2012)
4 times higher incidence among the poor (Muniyandi et al. 2007)
Case fatality rate of untreated case 0.32 (WHO 2012)
• TB treatment (DOTS)Cost of $100 per patientEffective at 90% (WHO 2012)
• Current DOTS coverage- average of 71%- bottom income quintile: 47%- top income quintile: 95%
04/10/2023
UPF for TB Treatment Over 1 Year for 1 Million Indians
12
TB deaths averted
Poorest 2nd Poorest Middle 2nd Richest Richest
Treat TB-infected with DOTS
DOTS coverage (~ 90%)
DOTS effectiveness
(~ 90%)
TB costs averted for households
Financial protection
benefits
04/10/2023
Benefits over 1 Year with UPF for 90% coverage of TB Treatment (per
million population)
13
Outcome Total Income
Quintile I (Poorest)
Income Quintile II (Poorer)
Income Quintile III (Middle)
Income Quintile IV
(Richer)
Income Quintile V (Richest)
1 TB deaths averted 80 40 25 12 3 0
2Private
expenditures crowded out
$29,000 6,000 6,000 7,000 6,000 4,000
3Money-
metric value of insurance
$9,000 5,000 2,000 1,000 1,000 0
Total cost of public program of $65,000
04/10/2023
Coping Mechanisms: Borrowing
14
• Without UPF, when faced with costly treatment, the poor borrow from peers or sell assets
• 50% of poor households in India borrow money/sell assets at high interest rates (Kruk et al. 2009)
• Assume the poor take a loan over 10 years at annual interest rate of 20% to subsidize TB treatment
04/10/2023
Benefits over 1 Year for 1 Million Indians with UPF for TB Treatment
15
Outcome Total Income
Quintile I (Poorest)
Income Quintile II (Poorer)
Income Quintile III (Middle)
Income Quintile IV
(Richer)
Income Quintile V (Richest)
1 TB deaths averted 150 100 50 0 0 0
2Private
expenditures crowded out
$70,000 0 15,000 25,000 20,000 10,000
3Money-
metric value of insurance
$10,000 0 3,000 4,000 2,000 1,000
Total cost of public program of $130,000
04/10/2023 16
Comparative Analysis – Ethiopia
Stéphane Verguet, Zachary Olson, Joseph Babigumira, Margaret Kruk,Kjell Arne Johansson, Carol Levin,
Rachel Nugent, Clint Pecenka, Mark Shrime,David Watkins, Dean Jamison
04/10/2023
Ethiopia
17